ArticleScientific reports2017
Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Improved high-throughput MHC typing for non-model species using long-read sequencing.Molecular ecology resources · 2022Pooled it
- Identification of expressed endogenous retroviral element associated long terminal repeats in devil facial tumour cells.Open biology · 2026Article
- Tyrosine kinase targeting uncovers oncogenic pathway plasticity in Tasmanian devil transmissible cancers.The EMBO journal · 2026Article
- No Evidence for Distinct Transcriptomic Subgroups of Devil Facial Tumor Disease (DFTD).Evolutionary applications · 2025Article
- NEUROENDOCRINE TUMORS NEARLY CAUSING EXTINCTION OF A MAMMAL.Transactions of the American Clinical and Climatological Association · 2025Article
- Differentially expressed growth factors and cytokines drive phenotypic changes in transmissible cancers.Discovery immunology · 2025Article
- Complex associations between cancer progression and immune gene expression reveals early influence of transmissible cancer on Tasmanian devils.Frontiers in immunology · 2024Article
- Tasmanian devil cathelicidins exhibit anticancer activity against Devil Facial Tumour Disease (DFTD) cells.Scientific reports · 2023Article
- Tasmanian devil cancer vaccine approved for testing.Nature · 2023Article
- Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours.Open biology · 2022Article
- Expression of the Nonclassical MHC Class I, Saha-UD in the Transmissible Cancer Devil Facial Tumour Disease (DFTD).Pathogens (Basel, Switzerland) · 2022Article
- Saving the Devils Is in the Details: Tasmanian Devil Facial Tumor Disease Can Be Eliminated with Interventions.Letters in biomathematics · 2022Article
- Disruption of Metapopulation Structure Reduces Tasmanian Devil Facial Tumour Disease Spread at the Expense of Abundance and Genetic Diversity.Pathogens (Basel, Switzerland) · 2021Article
- NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers.Journal of cancer research and clinical oncology · 2021Article
- The immunopeptidomes of two transmissible cancers and their host have a common, dominant peptide motif.Immunology · 2021Article
- Applied ecoimmunology: using immunological tools to improve conservation efforts in a changing world.Conservation physiology · 2021Article
- What Animal Cancers teach us about Human Biology.Theranostics · 2021Review
- Article
- The ecology and evolution of wildlife cancers: Applications for management and conservation.Evolutionary applications · 2020Article
- Transmissible Cancers in an Evolutionary Perspective.iScience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 3 countries.
Funding
Abstract
Devil facial tumour disease (DFTD) is a transmissible cancer devastating the Tasmanian devil (Sarcophilus harrisii) population. The cancer cell is the 'infectious' agent transmitted as an allograft by biting. Animals usually die within a few months with no evidence of antibody or immune cell responses against the DFTD allograft. This lack of anti-tumour immunity is attributed to an absence of cell surface major histocompatibility complex (MHC)-I molecule expression. While the endangerment of the devil population precludes experimentation on large experimental groups, those examined in our study indicated that immunisation and immunotherapy with DFTD cells expressing surface MHC-I corresponded with effective anti-tumour responses. Tumour engraftment did not occur in one of the five immunised Tasmanian devils, and regression followed therapy of experimentally induced DFTD tumours in three Tasmanian devils. Regression correlated with immune cell infiltration and antibody responses against DFTD cells. These data support the concept that immunisation of devils with DFTD cancer cells can successfully induce humoral responses against DFTD and trigger immune-mediated regression of established tumours. Our findings support the feasibility of a protective DFTD vaccine and ultimately the preservation of the species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.